In transplant-eligible patients with newly diagnosed multiple myeloma (MM), the novel anti-CD38 monoclonal antibody isatuximab (Sarclisa, Sanofi) more than doubles the odds ratio (OR) of minimal residual disease (MRD) negativity compared with a previous standard, according to results from a phase 3 trial.
Whether defined at a cutoff of 10-5 or 10-6, the MRD advantage of the arm containing isatuximab was “retained in all subgroups we assessed with similar benefit in patients with standard-